- Home
- SBRA
SBRA
Sabra Health Care REIT Inc.
as 04-23-2025 4:00pm EST
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $19.43 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.54 | EPS Growth: | 807.61 |
| 52 Week Low/High: | $13.55 - $20.03 | Next Earning Date: | 05-05-2025 |
| Revenue: | $702,638,000 | Revenue Growth: | 9.00% |
| Revenue Growth (this year): | 5.97% | Revenue Growth (next year): | 5.16% |
Stock Insider Trading Activity of Sabra Health Care REIT Inc. (SBRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cusack Catherine | SBRA | Director | Feb 21 '25 | Buy | $16.18 | 2,500 | $40,315.00 | 59,083 |
Latest Sabra Health Care REIT Inc. News
SBRA Breaking Stock News: Dive into SBRA Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Sabra Health Care REIT, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call
Argus Research
8 days ago
SBRA: Raising target price to $19.00
Argus Research
15 days ago
SBRA: Lowering target price to $18.00
Argus Research
22 days ago
SBRA: What does Argus have to say about SBRA?
Business Wire
a month ago
Sabra Health Care REIT, Inc. to Attend Deutsche Bank’s 2025 Healthcare REIT Summit
Argus Research
a month ago
SBRA: Rating increased to a BUY
Business Wire
a month ago
Sabra Health Care REIT, Inc. Announces Chief Investment Officer Transition
MT Newswires
a month ago
Truist Lifts Price Target on Sabra Health Care REIT to $18 From $17, Keeps Hold Rating
Compare SBRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SBRA Sabra Health Care REIT Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.